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Background: We have developed a novel and brief semi-structured psychotherapeutic intervention for patients
with advanced or metastatic cancer, called Managing Cancer And Living Meaningfully. We describe here the
methodology of a randomized controlled trial to test the efficacy of this treatment to alleviate distress and promote
well-being in this population.
Methods/Design: The study is an unblinded randomized controlled trial with 2 conditions (intervention plus usual
care versus usual care alone) and assessments at baseline, 3 and 6 months. The site is the Princess Margaret Cancer
Centre, part of the University Health Network, in Toronto, Canada. Eligibility criteria include: ≥ 18 years of age;
English fluency; no cognitive impairment; and diagnosis of advanced cancer. The 3–6 session intervention is
manualized and allows for flexibility to meet individual patients’ needs. It is delivered over a 3–6 month period and
provides reflective space for patients (and their primary caregivers) to address 4 main domains: symptom
management and communication with health care providers; changes in self and relations with close others; sense
of meaning and purpose; and the future and mortality. Usual care at the Princess Margaret Cancer Centre includes
distress screening and referral as required to in-hospital psychosocial and palliative care services. The primary
outcome is frequency of depressive symptoms and the primary endpoint is at 3 months. Secondary outcomes
include diagnosis of major or minor depression, generalized anxiety, death anxiety, spiritual well-being, quality of
life, demoralization, attachment security, posttraumatic growth, communication with partners, and satisfaction with
clinical interactions.
Discussion: Managing Cancer And Living Meaningfully has the potential to relieve distress and promote
psychological well-being in patients with advanced cancer and their primary caregivers. This trial is being
conducted to determine its benefit and inform its dissemination. The intervention has cross-national relevance and
training workshops have been held thus far with clinicians from North and South America, Europe, the Middle East,
Asia and Africa.
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Advanced or metastatic cancer is predictably associated
with challenges and burdens that may lead to symptoms
of depression and demoralization and fears of suffering, de-
pendency, and mortality [1]. The multiple physical symp-
toms, the dramatic alteration in support needs and in
personal relationships, the difficulty navigating a complex
health care system, and the threat of impending mortality
all may constitute pathways to distress in this population
[2]. The challenge for individuals in this circumstance is to
sustain a “double awareness” that allows them to remain
engaged in life while facing the imminence of physical de-
terioration, shortened survival, and death [3]. A variety of
individual and social factors may protect individuals in this
circumstance, but professional support may also be of
value to prevent and treat the distress that commonly
emerges in this population [4].
Clinically significant depressive symptoms may be fre-
quent in patients with advanced cancer and can be under-
stood as a final common pathway of distress, emerging in
response to the interaction of multiple disease-related, in-
dividual and psychosocial factors [1, 2, 5–7]. The most
prominent of these are the physical burden of disease, at-
tachment insecurity (i.e., worry about the availability of
supportive relationships and the capacity to make use of
them for emotional support), lower self-esteem, feelings of
hopelessness and impaired spiritual well-being [1, 2]. Al-
though many psychotherapeutic modalities have been
used to treat depression (e.g., cognitive behavior therapy
and interpersonal therapy), positive outcomes and sus-
tained improvement may be most likely when treatment is
directed at etiological and pathogenic factors that are
specific to the context in which disturbances arise [8]. Pre-
liminary findings in patients with advanced cancer also
suggest that psychological treatments for depression are
preferred over pharmacological ones [9], and that individ-
ual psychotherapy is preferred over group therapy because
sessions can be flexibly tailored to patients’ individual
needs, taking into account other clinic appointments and
fluctuations in health status [10–13].
To address the relative lack of evidence-based individual
therapies tailored for this population, we have developed a
novel, brief, semi-structured, individual, manualized psy-
chotherapeutic intervention to alleviate distress and pro-
mote well-being in patients with advanced or metastatic
cancer. This psychotherapy, called Managing Cancer And
Living Meaningfully (CALM) [4, 14, 15], addresses the
specific problems and risk factors that contribute to the
emergence of depressive symptoms in this circumstance
[1, 2]. It shares features with manualized supportive-
expressive [16–24], cognitive-existential [25, 26], and
meaning-centered [27] group psychotherapies applied to
patients with advanced and terminal disease. CALM pro-
vides support and reflective space for the processing ofthoughts and emotions evoked by this traumatic condition
and facilitates the resolution of practical and existential
questions that face individuals with advanced disease.
Such an intervention has the potential not only to relieve
distress but also to promote psychological growth [28, 29].
The purpose of this phase III randomized controlled trial
(RCT) is to evaluate the efficacy of the CALM interven-
tion in patients with advanced cancer.
Methods/Design
The study is an unblinded RCT with 2 trial conditions
(intervention plus usual care versus usual care alone)
and assessments at baseline, 3 and 6 months. The pri-
mary outcome is depressive symptoms as assessed by
the Patient Health Questionnaire-9 (PHQ-9). The pri-
mary endpoint is at 3 months and the secondary end-
point is at 6 months. The site is the Princess Margaret
Cancer Centre, part of the University Health Network
and Canada’s largest comprehensive cancer treatment
and research center where more than 10,000 patients are
assessed annually and more than 1,000 patients attend out-
patient clinics daily [30]. The phase III protocol and related
documents were approved by the Research Ethics Board
(REB) of the University Health Network on 5 February
2010 (UHN REB #09-0855-C). A number of subsequent
amendments to allow a phase IIA non-randomized and
a phase IIB randomized pilot were approved by the
REB prior to the final amendment and launch of this
phase III trial in January 2012. Patients are recruited
from eight approved tumor sites: gastrointestinal, lung,
gynecological, breast, genitourinary, sarcoma, melan-
oma and endocrine. Patients are approved for trial en-
rollment by the principal investigators (GR, SH, CL)
prior to randomization.
Inclusion/Exclusion Criteria
The inclusion criteria are: 1) ≥ 18 years of age; 2) fluency
in English; 3) no cognitive impairment indicated in the
medical record or by the attending oncologist; and 4) a
confirmed diagnosis of stage III or IV lung cancer, any
stage of pancreatic cancer (due to the aggressiveness of this
disease), unresectable cholangiocarcinoma, unresectable
liver cancer, unresectable ampullary or peri-ampullary can-
cer or other stage IV (metastatic) gastrointestinal cancer,
stage III or IV ovarian and fallopian tube cancers, or other
stage IV gynecological cancer; and stage IV breast, genito-
urinary, sarcoma, melanoma, or endocrine cancers (all of
the above with expected survival of 12–18 months). Pa-
tients meeting inclusion criteria undergo a brief interview
with a research staff member to identify the following
exclusion criteria: 1) major communication difficulties; 2)
inability to commit to the required 3–6 psychotherapy
sessions (i.e., too ill to participate, lack of transportation,
insufficient motivation due to lack of distress); 3)
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Short Orientation-Memory-Concentration (SOMC) test
[31], unless deemed suitable at the recruiter’s discre-
tion, or due to brain metastases; 4) actively receiving
psychiatric or psychological intervention in the Depart-
ment of Supportive Care (formerly the Department of Psy-
chosocial Oncology and Palliative Care) at the Princess
Margaret Cancer Centre at the time of study approach; 5)
refusal to accept randomization; and 6) prior treatment
with CALM therapy during an earlier phase of the study.
Procedure
Research staff screen the outpatient oncology clinic lists
of eight solid tumor sites on a daily basis. Patients with
advanced cancer are identified and mailed introductory
letters concerning the study. These patients are
approached by research staff for study recruitment
while attending clinic appointments. During the recruit-
ment process, the study design and intervention are de-
scribed to patients and the inclusion/exclusion criteria
are reviewed. Participants are also informed at study re-
cruitment that if they are not randomized to receive
CALM therapy, they will be offered the opportunity to
receive CALM after completion of the final 6-month as-
sessment. After providing written informed consent,
cognitive functioning and other exclusion criteria are
assessed, medical and demographic information is col-
lected, baseline measures are administered, a diagnostic
interview for depression is conducted, and eligible pa-
tients are randomized. Some patients who screen fail
may be eligible for reapproach at a later date.
Trial conditions
Participants in the intervention group receive usual care
plus CALM, a semi-structured psychotherapy designed
for patients with advanced cancer. CALM was developed
based on empirical data, clinical observations, and the
theoretical foundations of relational [32], attachment
[33] and existential [34] theory.
CALM includes 3–6 individual psychotherapy ses-
sions, each approximately 45–60 minutes in length, de-
livered over 3-6 months. The sessions cover 4 domains: 1)
symptom management and communication with health
care providers; 2) changes in self and relations with close
others; 3) sense of meaning and purpose; and 4) the future
and mortality [14, 15]. All domains are addressed with
each patient, but the time devoted to each and the
sequence in which they are addressed is based on the
salience of concerns for each patient during the session.
Therapists aim to deliver at least 3 sessions within 3
months. Non-compliance with intervention is defined as
having less than 3 sessions over the course of the trial.
CALM is delivered by specially trained therapists, pri-
marily master's level social workers, in the Department ofSupportive Care at the Princess Margaret Cancer Centre.
Therapists are trained and supervised by the clinician in-
vestigators who developed the intervention (GR, SH). The
participant’s primary caregiver (e.g., spouse/partner, adult
son/daughter, family member), or significant other, is in-
vited to participate in one or more of the therapy sessions,
when acceptable to the patient.
At any time during the intervention, patients consid-
ered by the therapist to be at acute risk for suicide, or
who demonstrate significant worsening of depression or
other psychiatric co-morbidities that require treatment,
will be referred for psychiatric assessment and treatment
in the Department of Supportive Care. This may include
pharmacotherapy or other psychiatric interventions.
Participants in the control group receive usual care
alone. At the Princess Margaret Cancer Centre this in-
cludes routine treatment and follow-up in medical, surgical
and/or radiation outpatient oncology clinics, as well as a
clinic-based distress screening program, referred to as
DART (Distress Assessment and Response Tool) [35], with
results provided at the time of the clinic visit to oncology
clinic staff. Clinic staff may refer any patient for specialized
psychosocial oncology services (provided by trained volun-
teers and by social work, psychiatry and psychology staff)
or to palliative care, based on clinical judgment, patient re-
quests and/or distress screening scores. In the event that a
usual care participant reports suicidal intent, the principal
investigators are contacted and the patient is assessed by a
psychiatrist from the Department of Supportive Care.
Approximately one third of patients with metastatic
cancer are referred for psychosocial care at the Princess
Margaret, two thirds of whom are seen by a social worker
[36]. Approximately 65 % of social work consultations in-
volve provision of practical or instrumental care (e.g., ur-
gent drug coverage, referral for admission to the Acute
Palliative Care Unit, complex continuing care placement,
etc.); 35 % of consultations involve brief supportive inter-
actions to alleviate emotional distress in patients and/or
family members. Control participants do not typically re-
ceive structured counseling from social work as part of
usual care. Of those referred to psychiatry or psychology,
less than one third receive a structured or semi-structured
psychotherapy. Overall, less than 10 % of patients with
metastatic cancer at the Princess Margaret Cancer Centre
receive any form of semi-structured psychotherapy that
is similar to CALM therapy. To avoid contamination
of the control group in the event of a referral to the
Department of Supportive Care, controls referred for
psychosocial care will be seen, if possible, by therapists
in the department who have not received prior train-
ing in CALM therapy (i.e., non-CALM-trained
therapists). Contamination will be monitored and
documented and is defined as having two or more
sessions with a CALM-trained therapist.
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The treatment integrity of the intervention arm is ensured
by means of weekly group supervision of therapists with
case presentations. CALM sessions are audio-recorded,
and therapists document sessions in a written report.
Senior clinicians (GR, SH) assess overall and topic-specific
competencies using treatment integrity rating scales
adapted from Spiegel and Spira’s [18] tools. Evaluations are
discussed with each therapist to improve competencies.
Randomization
Permuted block randomization is used to allocate partic-
ipants to a trial condition with stratification by PHQ-9
score (< or ≥ 10). Stratification ensures that highly de-
pressed individuals will be balanced in both arms. The
randomization process is managed by the Department
of Biostatistics at the Princess Margaret Cancer Centre,
which is independent of the trial team.
Outcome measures
The primary outcome measure is the Patient Health
Questionnaire-9 (PHQ-9) [37], a reliable and valid 9-
item measure of depression that has been used widely
with advanced cancer patients [38]. This brief measure
is a subscale of the Patient Health Questionnaire (PHQ),
a patient self-report version of the Primary Care Evalu-
ation of Mental Disorders (PRIME-MD), a widely used
tool to screen for mental health disorders in primary
care [39]. Two additional questions on the PHQ-9 in-
clude: question 9a which assesses suicidal intent if a pa-
tient endorses suicidal ideation (i.e., “Is there a chance
you would do something to end your life?” Yes/No); and
question 10 which assesses functional impairment (i.e.,
“How difficult have these problems made it for you to
do your work, take care of things at home, or get along
with other people?” Not difficult at all/Somewhat diffi-
cult/Very difficult/Extremely difficult).
The secondary outcome measures assess domains hy-
pothesized to respond directly or indirectly to the inter-
vention through its potential impact on communication
with health care providers, shifts in personal relationships
or other factors. A portion of the Mood Disorders and
Optional Disorders Module from the Structured Clinical
Interview for Diagnostic and Statistical Manual of Mental
Disorders (DSM) (SCID) [40] (SCID-1 Research Version
for DSM-IV-TR Axis 1 Disorders, January 2010) is admin-
istered in this study. The SCID is a semi-structured inter-
view that allows researchers to make diagnoses of major
and minor depression consistent with DSM diagnostic
criteria [41].
The Generalized Anxiety Disorder-7 (GAD-7) [42] is a
widely used and validated 7-item self-report measure de-
signed to screen and assess the frequency of GAD symp-
toms. It is a subscale of the PRIME-MD [39]. An eighthitem, rating how difficult these symptoms have made it
to do work, take care of things at home, or get along
with other people, has been included.
The Functional Assessment of Chronic Illness Therapy-
Spiritual Well-being Scale (FACIT-Sp) [43] is a 12-item
self-report measure of spiritual well-being, assessing the
sense of meaning, peace and faith, that has been widely
used in palliative care research [44, 45].
The Posttraumatic Growth Inventory (PTGI) [46–48], a
21-item self-report scale that measures positive psycho-
logical changes after trauma, has been used as a measure
of psychological growth in response to the psychological
trauma of cancer [49] and as an outcome measure for
intervention studies [50, 51]. The PTGI provides a total
score based on the experience of new possibilities and
spiritual change, growth in personal strength, relations
with others, and appreciation of life.
The Quality of Life at the End of Life-Cancer Scale
(QUAL-EC) [52] is a measure of quality of life in patient
populations near the end of life. We omitted the symptom
control subscale, thereby reducing this self-report measure
to 14 items.
Death anxiety is assessed using the 15-item Death and
Dying Distress Scale (DADDS), which we have devel-
oped for use in advanced cancer [53]. Unlike other death
anxiety measures (e.g., [54]), the DADDS is designed for
populations facing imminent death. It addresses fears
about the dying process, and about lost opportunities
and self-perceived burden placed on others as a result of
impending mortality.
The Demoralization Scale (DS) [55] is a 24-item self-
report measure that assesses loss of meaning and pur-
pose, disheartenment, and helplessness.
Attachment security is assessed using the 16-item
modified Experiences in Close Relationships Inventory
(ECR-M16) [56], tailored for use with advanced cancer
patients. It assesses attachment avoidance (i.e., discomfort
with closeness and discomfort depending on others) and
attachment anxiety (i.e., fear of rejection or abandonment).
Participants who are married, common-law, or in a
long-term relationship will be asked to complete the
ten-item Couple Communication Scale (CCS) [57],
which is concerned with an individual’s feelings, beliefs,
and attitudes about the communication in his/her rela-
tionship; the CCS is taken from the PREPARE/ENRICH
Inventory [57].
Lastly, the Clinical Evaluation Questionnaire (CEQ) is
a seven-item measure that we have newly developed to
assess the extent to which individuals feel emotionally
supported by clinical services in the domains relevant to
CALM therapy. For intervention participants, the CEQ
refers to the patients’ experience of CALM therapy. For
control participants, the CEQ refers to the patient’s in-
teractions with the health care team at the Princess
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See Additional file 1 for this measure.
Additional data collected will include: demographics,
medical and psychiatric history, performance status, and
disease-related symptom severity. Performance status is
rated by research staff with patient input at all study
time points using the Karnofsky Performance Status
(KPS) scale [58]. A shortened version of the Memorial
Symptom Assessment Scale (MSAS) [59] is used to
measure the presence and severity of 28 common phys-
ical symptoms of cancer.
Initial power calculations
Although the primary endpoint was designated at 3
months, sample size calculations took into account the sec-
ondary 6-month endpoint in order to sufficiently power
the trial to examine outcomes at study end. We used the
following sample size formula for an analysis of covariance
(ANCOVA) design in which two groups are compared at
follow-up, controlling for baseline scores [60]:
n ¼ 2 ZA þ ZBð Þ2 1 – r2
 
=d2
  þ 1
where d = (X1 – X2)/SD, i.e., Cohen’s d [61];
n = sample size per treatment group required at
follow-up;
ZA = 1.96, the z-score associated with a two tailed test
at alpha 0.05;
ZB = 0.842, the z-score associated with a desired
power of 0.80; and
r = correlation between measurements at baseline and
study end.
Based on this longitudinal study: [61] (CIHR #MOP
62861) of metastatic gastrointestinal and lung cancer pa-
tients [1, 2], we observed a correlation of 0.72, n = 137,
between depression scores at baseline and 6 months. We
used 0.70 as our estimate of r. We planned to detect d =
0.405, a small to medium sized effect [61], consistent with
prior work [9, 62].
Substituting these values into the equation results in:
n ¼ 2 1:96þ 0:842ð Þ2 1–0:702 =0:4052 þ 1
¼ 2 7:851ð Þ 0:51ð Þ= 0:164ð Þ½  þ 1 ¼ 49:8 e50
A minimum of 50 participants per group was initially
required at study end.
The following formula was used to adjust for attrition
and non-compliance with intervention (i.e., having less
than three CALM sessions) [63, 64]:
nb ¼ ne 1=pð Þ 1=c2
 
where nb = sample size required at baseline per treat-
ment group;ne = sample size required at endpoint per treatment
group;
p = proportion of participants who will reach study
end; and
c = proportion of participants compliant with
intervention.
We initially estimated a trial completion rate of 60 %
and compliance rate of 80 % based on prior research
[38]. Substituting relevant values into the equation re-
sults in:
nb ¼ 50 1=0:60ð Þ 1=0:802
  ¼ 50 1:667ð Þ 1:563ð Þ ¼ 130:3 e131
Therefore, 131 participants per group or 262 total par-
ticipants will be required at baseline. Based on previous
experience [1, 2], trial recruitment was anticipated to
last 4.5 years.
Sample size recalculation
A sample size recalculation was conducted in February
2014 in light of observed differences from initial estimates
in rates of attrition and compliance. This procedure was
undertaken with no awareness or examination of treat-
ment effects. The observed correlation between depres-
sion scores at baseline and 6 months was 0.50, n = 112.
To detect an effect size of 0.405 with a 2-tailed test, the
required n per group is 73 at study end. Approximately
75 % of participants had reached study end at 6 months
and 90 % of participants were compliant with interven-
tion. Adjusting for these factors, a minimum of 121
participants per group or 242 participants overall will
be required at baseline. Note that contamination of
control participants (i.e., having two or more sessions
with a CALM-trained therapist) was negligible and was
not adjusted for.
Proposed analyses
Analyses will be by intention to treat. ANCOVA will be
used to test for outcome differences between experimen-
tal and control groups at follow-up, controlling for base-
line scores and covariates, specifically age, gender and
symptom burden from disease. Sensitivity analyses, in-
cluding complete case analysis and multiple imputation,
will be conducted to assess the impact of missing values.
Linear mixed effects modeling will be used to test for
group differences in trajectory over time. Intervention
participants are expected to show greater benefit (i.e.,
less distress or greater well-being) over time relative to
control participants. Structural equation modeling and
factor analysis may also be used to study treatment ef-
fects on combined or composite outcomes.
The outcome of death anxiety may require special con-
sideration, since death anxiety scores at baseline in the
very low range can represent minimization or non-
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tions). Non-reflective individuals may increase in death
anxiety as their disease progresses and as avoidant psycho-
logical strategies become less effective with physical de-
cline. Analyses will, therefore, examine the effect of
removing individuals with low death anxiety scores at
baseline (i.e., DADDS < 15). Effective psychotherapeutic
intervention may actually be associated with increased
death anxiety due to the processing of such concerns,
thereby weakening the power to detect significant treat-
ment effects.Discussion
CALM therapy is a novel psychotherapeutic intervention
that we have developed to alleviate distress and to pro-
mote psychological growth and well-being in patients
with advanced or metastatic cancer. Unique features of
this supportive-expressive therapy include its theoretical
foundation in relational, attachment and existential
theory, its tailored focus on the problems of advanced
cancer, the inclusion of primary informal caregivers
in one or more sessions of the intervention, and the
potential for recruitment of participants from a clinic-
based population. Although depression is specified as
the primary outcome, we also place great importance on
the secondary outcome measures, which we believe are
highly relevant to the problem of advanced cancer and
may be improved by the intervention.
There are particular challenges in an RCT of this
kind. These include the identification of participants
motivated to engage in psychotherapy at the time of re-
cruitment, recruitment and retention of patients with
advanced illness, and the possibility that outcomes will
be affected by dramatic changes in clinical status that
may occur during the course of advanced cancer. The
clinic-based recruitment strategy is facilitated by the
engagement of the research team with the oncology
clinic staff. This clinic-based approach will be of great
value to inform our understanding of the benefit of
CALM in both depressed and non-depressed individ-
uals who were not necessarily seeking professional psy-
chosocial care.
We are fortunate to have recruited a group of commit-
ted and experienced psychosocial clinicians, who have
been intensively trained and supervised to deliver the
CALM intervention. Preliminary qualitative [4] and quan-
titative pilot studies [65] have provided support for the
feasibility and value of CALM therapy, but the large phase
III RCT described here will provide a more definitive
assessment of its potential efficacy. Such evidence will
determine whether it can be justified to routinely incor-
porate CALM into the comprehensive care of patients
with advanced cancer.Trial status
The trial is currently underway. Trial Registration: Clinical
Trials.gov NCT01506492.
Additional file
Additional file 1: The Clinical Evaluation Questionnaire (CEQ)*.
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